



Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

05/07/2025 07:04:13

Main Information

Primary registry identifying number

LBCTR2021034776

Protocol number

CKJX839C12301

MOH registration number

Study registered at the country of origin

Yes

Study registered at the country of origin: Specify

Type of registration

Prospective

Type of registration: Justify

N/A

Date of registration in national regulatory agency

Primary sponsor

Novartis Pharma Services inc.

Primary sponsor: Country of origin

Novartis Pharmaceuticals

Date of registration in primary registry

11/02/2025

Date of registration in national regulatory agency

Public title

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

Acronym

Scientific title

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-16)

Acronym

Brief summary of the study: English

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C).

This is a two-part (1 year double-blind inclisiran versus placebo / 1 year open-label inclisiran) multicenter study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C) on stable standard of care background lipid-lowering therapy. The primary objective is to demonstrate superiority of inclisiran compared to placebo in reducing LDL-C (percent change) at Day 330.

Brief summary of the study: Arabic

[يتبعه إنكليسيران مفتوح اللصاقفة 1دراسة متعددة المراكز، عشوائية التوزيع من قسمين (إنكليسيران مزدوج التعمية مقابل الدواء الوهمي) السنة (سنة) المصابين بفرط كوليسترول الدم العائلي18 إلى أقل من 12] لتقييم سلامة إنكليسيران وقدرة تحملته وفعاليتها لدى المراهقين (من 2السنة [(ORION-16) متغاير الزيجوت وبارتفاع الكوليسترول الضار (أوريون-

Health conditions/problem studied: Specify





Heterozygous Familial Hypercholesterolemia

Interventions: Specify

Drug: Inclisiran
Drug: Placebo

Key inclusion and exclusion criteria: Inclusion criteria

Heterozygous Familial Hypercholesterolemia (HeFH) diagnosed either by genetic testing or on phenotypic criteria
Fasting LDL-C >130 mg/dL (3.4 mmol/L) at screening
Fasting triglycerides <400 mg/dL (4.5 mmol/L) at screening
On maximally tolerated dose of statin (investigator's discretion) with or without other lipid-lowering therapy; stable for ≥ 30 days before screening
Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m² at screening

Key inclusion and exclusion criteria: Gender

Both

Key inclusion and exclusion criteria: Specify gender

Key inclusion and exclusion criteria: Age minimum

12

Key inclusion and exclusion criteria: Age maximum

17

Key inclusion and exclusion criteria: Exclusion criteria

Homozygous familial hypercholesterolemia (HoFH)
Active liver disease
Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome
Major adverse cardiovascular events within 3 months prior to randomization
Previous treatment with monoclonal antibodies directed towards PCSK9 (within 90 days of screening)
Recent and/or planned use of other investigational medicinal products or devices
Other protocol-defined inclusion/exclusion criteria may apply

Type of study

Interventional

Type of intervention

Pharmaceutical

Type of intervention: Specify type

N/A

Trial scope

Therapy

Trial scope: Specify scope

N/A

Study design: Allocation

Randomized controlled trial

Study design: Masking

Blinded (masking used)

Study design: Control

Placebo

Study phase

3

Study design: Purpose

Treatment

Study design: Specify purpose

N/A

Study design: Assignment

Parallel

Study design: Specify assignment

N/A

IMP has market authorization

Yes, Worldwide

IMP has market authorization: Specify

European Union, United Arab Emirates, Great Britain

Name of IMP

inclisiran

Year of authorization

Month of authorization

Type of IMP

Others

Pharmaceutical class



cholesterol-lowering small interfering ribonucleic acid (siRNA) that inhibits the production of proprotein convertase subtilisin/kexin type 9

Therapeutic indication

heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C)

Therapeutic benefit

to demonstrate superiority of inclisiran compared to placebo in reducing LDL-C (percent change) at Day 330 in adolescents (12 to less than 18 years) with heterozygous familial hypercholesterolemia and elevated LDL-cholesterol

Study model

N/A

Study model: Explain model

N/A

Study model: Specify model

N/A

Time perspective

N/A

Time perspective: Explain time perspective

N/A

Time perspective: Specify perspective

N/A

Target follow-up duration

Target follow-up duration: Unit

Number of groups/cohorts

Biospecimen retention

Samples with DNA**

Biospecimen description

Blood samples collected will be analyzed at Medpace Laboratories, central lab

Target sample size

4

Actual enrollment target size

3

Date of first enrollment: Type

Actual

Date of first enrollment: Date

31/08/2021

Date of study closure: Type

Actual

Date of study closure: Date

16/03/2025

Recruitment status

Complete

Recruitment status: Specify

Date of completion

19/11/2022

IPD sharing statement plan

Yes

IPD sharing statement description





Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Additional data URL

<https://clinicaltrials.gov/ct2/show/NCT04652726?cond=heterozygous+familial+hypercholesterolemia&draw=2&rank=2>

Admin comments**Trial status**

Approved

Secondary Identifying Numbers

| Full name of issuing authority | Secondary identifying number |
|--------------------------------|------------------------------|
| NCT04652726 | Clinical trials.gov |

Sources of Monetary or Material Support

| Name |
|-------------------------------|
| Novartis Pharma Services inc. |

Secondary Sponsors

| Name |
|------|
| NA |

Contact for Public/Scientific Queries

| Contact type | Contact full name | Address | Country | Telephone | Email | Affiliation |
|--------------|-------------------|----------|---------|---------------|--|--|
| Public | Selim Jambart | Beirut | Lebanon | 961 3 406 001 | sjambart@dm.net.lb | Hotel Dieu De France |
| Scientific | Hind Khairallah | Sinelfil | Lebanon | 01512002#271 | Hind.khairallah@fattal.com.lb | Khalil Fattal et Fils s.a.l. |
| Public | Hala Tfayli | Beirut | Lebanon | 71729759 | HT31@AUB.LB | American University of Beirut Medical Center |



Centers/Hospitals Involved in the Study

| Center/Hospital name | Name of principles investigator | Principles investigator speciality | Ethical approval |
|--|---------------------------------|------------------------------------|------------------|
| Hotel Dieu De France | Selim Jambart | Endocrinology | Approved |
| American University of Beirut Medical Center | Hala Tfayli | Pediatric Endocrinology | Approved |

Ethics Review

| Ethics approval obtained | Approval date | Contact name | Contact email | Contact phone |
|--|---------------|--------------|----------------|--|
| Hotel Dieu de France | 21/12/2020 | Sami Richa | cue@usj.edu.lb | 961421229 |
| American University of Beirut Medical Center | 28/06/2021 | Fuad Ziyadeh | irb@aub.edu.lb | 00961 -1-350000 or 1 374374, ext: 5445 |

Countries of Recruitment

| Name |
|--------------------------|
| Lebanon |
| Australia |
| Germany |
| Hungary |
| Norway |
| Spain |
| United States of America |

Health Conditions or Problems Studied

| Condition | Code | Keyword |
|--|--------------------------------------|--|
| heterozygous familial hypercholesterolemia | Hyperlipidaemia, unspecified (E78.5) | heterozygous familial hypercholesterolemia |

Interventions

| Intervention | Description | Keyword |
|---|---|--------------------------------------|
| Informed Consent/assent form discussion; Inclusion/exclusion assessment; physical examination; neurological examination; blood and urine samples collection; IMP dispensation | Informed Consent/assent form discussion; Inclusion/exclusion assessment; physical examination; neurological examination; blood and urine samples collection; IMP dispensation | ICF, IMP , Lab tests, physical exams |



Primary Outcomes

| Name | Time Points | Measure |
|--|---------------------|---------------------|
| Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) | baseline to Day 330 | baseline to Day 330 |
| Demonstrate superiority of inclisiran compared to placebo in reducing LDL-C [percent change] | Day 330 (Year 1) | Day 330 (Year 1) |

Key Secondary Outcomes

| Name | Time Points | Measure |
|---|--------------------------------------|--------------------------------------|
| Time-adjusted % change in LDL-C from baseline | Baseline, after Day 90 up to Day 330 | Baseline, after Day 90 up to Day 330 |
| Absolute change in LDL-C from baseline to Day 330 | Baseline and Day 330 | Baseline and Day 330 |
| % change in apolipoprotein B (Apo B), lipoprotein (a) [Lp(a)], non-high density lipoprotein cholesterol (non-HDL-C), and total cholesterol from baseline to Day 330 | Baseline and Day 330 | Baseline and Day 330 |
| % change and absolute change in LDL-C from baseline up to Day 720 | Baseline, up to Day 720 | Baseline, up to Day 720 |
| % change and absolute change in other lipoproteins and lipid parameters | Baseline, up to Day 720 | Baseline, up to Day 720 |
| % change and absolute change in proprotein convertase subtilisin/kexin type 9 (PCSK9) | Baseline, up to Day 720 | Baseline, up to Day 720 |



Trial Results

Summary results

Study results globally

Date of posting of results summaries

Date of first journal publication of results

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files